AKT/GSK3 signaling pathway and schizophrenia by Effat S. Emamian
REVIEW ARTICLE
published: 15 March 2012
doi: 10.3389/fnmol.2012.00033
AKT/GSK3 signaling pathway and schizophrenia
Effat S. Emamian*
Advanced Technologies for Novel Therapeutics (ATNT), Newark, NJ, USA
Edited by:
Jean-Martin Beaulieu, Duke
University Medical Center, USA
Reviewed by:
Claudia Bagni, Catholic University
of Leuven Medical School, Belgium
Xiaohua Li, University of Alabama
at Birmingham, USA
Ali Salahpour, University of Toronto,
Canada
*Correspondence:
Effat S. Emamian, Advanced
Technologies for Novel
Therapeutics, 211 Warren Street,
Newark, NJ 07103, USA.
e-mail: emame@atnt-usa.com
Schizophrenia is a prevalent complex trait disorder manifested by severe neurocognitive
dysfunctions and lifelong disability. During the past few years several studies have
provided direct evidence for the involvement of different signaling pathways in
schizophrenia. In this review, we mainly focus on AKT/GSK3 signaling pathway in
schizophrenia. The original study on the involvement of this pathway in schizophrenia
was published by Emamian et al. in 2004. This study reported convergent evidence
for a decrease in AKT1 protein levels and levels of phosphorylation of GSK-3β in
the peripheral lymphocytes and brains of individuals with schizophrenia; a significant
association between schizophrenia and an AKT1 haplotype; and a greater sensitivity to
the sensorimotor gating-disruptive effect of amphetamine, conferred by AKT1 deficiency. It
also showed that haloperidol can induce a stepwise increase in regulatory phosphorylation
of AKT1 in the brains of treated mice that could compensate for the impaired function of
this signaling pathway in schizophrenia. Following this study, several independent studies
were published that not only confirmed the association of this signaling pathway with
schizophrenia across different populations, but also shed light on the mechanisms by
which AKT/GSK3 pathway may contribute to the development of this complex disorder.
In this review, following an introduction on the role of AKT in human diseases and
its functions in neuronal and non-neuronal cells, a review on the results of studies
published on AKT/GSK3 signaling pathway in schizophrenia after the original 2004 paper
will be provided. A brief review on other signaling pathways involved in schizophrenia
and the possible connections with AKT/GSK3 signaling pathway will be discussed.
Moreover, some possible molecular mechanisms acting through this pathway will be
discussed besides the mechanisms by which they may contribute to the pathogenesis
of schizophrenia. Finally, different transcription factors related to schizophrenia will
be reviewed to see how hypo-activity of AKT signaling pathway may impact such
transcriptional mechanisms.
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INTRODUCTION
Schizophrenia is a severe mental disorder with a lifetime preva-
lence of 1% throughout the world population (Stilo and Murray,
2010). This highly prevalent mental disorder is typically associ-
ated with progressive functional decline, lifelong disability and
tremendous suffering (Sadock et al., 2009). Unlike other neu-
ropsychiatric disorders such as Parkinson’s disease, no single
anatomical abnormality is consistently observed in schizophrenia,
nor there are any biochemical tests that can confirm the clinical
diagnosis. Case identification usually begins with the observation
of positive symptoms such as delusional ideas, hallucinations,
disordered thinking, often with a later emergence of negative
symptoms, including low levels of emotional arousal, mental
activity and social drive (Sadock et al., 2009). Furthermore, there
is increasing recognition of several cognitive impairments in
this disorder, particularly in attention, memory, and executive
functions, which equally contribute to schizophrenia’s disabil-
ity. Although it is believed that multiple pathological processes
can lead to schizophrenia, we have neither identified them nor
linked them to the various clinical manifestations of the disorder
(Sadock et al., 2009).
Several linkage and association studies, including a few
genome-wide association studies (GWAS), have been performed
during the past decade to identify genetic susceptibilities to the
disease. A few review articles have nicely reviewed recent associa-
tion studies on large schizophrenia cohorts (Tiwari et al., 2010).
Such studies identified and replicated further loci in well-powered
cohorts (Tiwari et al., 2010). Moreover, over the past 4 years
there has been a significant interest in human Copy Number
Variants (CNVs). Several deletions that were recently identified
in schizophrenia, such as 1q21.1; 2p16.3; 15q11.2; 15q13.3, have
also been found in other neurodevelopmental disorders (Tiwari
et al., 2010).
Despite identification of several genetic variations that have
been repeatedly reproduced in several populations, many stud-
ies have been inconclusive. The limited success in detection of
genetic factors has led scientists to come to a general consensus
that the disease is not caused by the dysfunction of a specific
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molecule or pathway. Most likely schizophrenia is caused by
the altered function or expression of many genes, which may
individually contribute only to a small risk, but their collective
dysfunctional effects interfere with the function of several biolog-
ical pathways that eventually produce the clinical picture we know
as schizophrenia (Williams et al., 2009).
AKT AND HUMAN DISEASES
Deregulation of AKT signaling pathway is directly associated with
some of the most prevalent and incurable human diseases (Blain
and Massague, 2002; Liang et al., 2002; Shin et al., 2002; Viglietto
et al., 2002; Chen et al., 2003; Emamian et al., 2003, 2004; Brazil
et al., 2004; Colin et al., 2005; Griffin et al., 2005). It is now well
established that the hyperactivity of AKT is part of the pathologic
process in several types of the most common human malignan-
cies (Brazil et al., 2004), including breast cancer, prostate cancer,
lung cancer, gastrointestinal tumors, pancreatic cancer, hepato-
cellular carcinoma, thyroid cancer, and CNS malignancies (such
as glioblastoma or gliomas). Moreover, impairment of AKT sig-
naling pathway in a number of neurodegenerative brain disorders
such as Alzheimer disease, Huntington disease, spinocerebellar
ataxia type 1 (SCA1) and amyotrophic lateral sclerosis (ALS),
have been reported during the past few years (Saudou et al., 1998;
Chen et al., 2003; Emamian et al., 2003; Kaspar et al., 2003; Colin
et al., 2005; Griffin et al., 2005).
In Alzheimer disease, evidence for an increased AKT acti-
vation and the subsequent increase in the phosphorylation of
several AKT substrates in the brain tissue of patients has been
reported (Griffin et al., 2005). In Huntington disease, in vitro
studies have shown that huntingtin is a substrate of AKT, and
the phosphorylation of huntingtin by AKT is crucial for mediat-
ing the neuroprotective effects of IGF-1. Furthermore, changes in
AKT signaling in an animal model of Huntington disease, as well
as in patients with Huntington disease, are also reported (Saudou
et al., 1998; Colin et al., 2005). In SCA1, Chen et al. (2003) reports
a regulatory role of AKT in the association of ataxin-1 with 14-3-3
through the phosphorylation of Ser-776 of ataxin-1, which mod-
ulates the neurotoxicity of ataxin-1 (Emamian et al., 2003). In
ALS, IGF-1 stimulates the activity of AKT in the spinal cord and
prolongs the lifespan of the mouse model of ALS, by increasing
the survival of motor neurons (Kaspar et al., 2003).
Using a reverse protein-to-gene approach, we reported con-
vergent evidence for the impairment of AKT/GSK3 signaling
pathway in schizophrenia (Emamian et al., 2004), including a
significant association between schizophrenia and an AKT1 hap-
lotype in U.S. families (Caucasian of Northern European origin).
The genetic association of AKT1 with schizophrenia was later
confirmed in several other populations (Ikeda et al., 2004; Schwab
et al., 2005; Bajestan et al., 2006). Taken together, it seems that the
genetic association of AKT with schizophrenia is not limited to
a specific genetic background and is reproducible in populations
with different genetic backgrounds.
The main advantage of studies on signaling molecules in
complex human disorders with unknown etiology, such as
schizophrenia and autism, is their potential for discovering the
abnormal function of proteins involved in the pathogenesis
regardless the actual causative factor, whether it is genetic or
environment or the interplay between them. Another important
advantage of studies on signaling proteins such as AKT is their
capacity for identification of sequence specific activation or inhi-
bition sites on molecules involved in the disease process. Such
specific sites could be ultimately used as selective targets for high
throughput screening of small molecules or chemical entities,
to discover novel therapeutics for several disorders. Therefore,
despite the fact that schizophrenia is complex and extremely dif-
ficult to understand at the molecular level, dissecting the role
of signaling molecules such as AKT or GSK3 in such a complex
disorder has obvious therapeutic implications.
AKT IN NON-NEURONAL CELLS
AKT (also known as PKB) is a relatively new member of the AGC
kinase family. It was discovered in early 1990s as a major regula-
tor of cell cycle (Brazil et al., 2004). After almost two decades, over
30,000 papers have been published (∼7000 in the past year) that
show its major regulatory role in multiple aspects of cellular func-
tion. Figure 1 summarizes the molecular targets of AKT signaling
pathway.
AKT has emerged as the focal point for many signal trans-
duction pathways, regulating multiple cellular processes such as
glucose metabolism, transcription, apoptosis, cell proliferation,
angiogenesis, and cell motility (Figure 1, www.cellsignal.com,
Kandel and Hay, 1999). Stimulation of its catalytic activity is
triggered by PI3 kinase and results from the PtdIns(3,4,5)P3-
dependent recruitment of AKT from the cytoplasm to the mem-
brane, as well as the phosphorylation of two regulatory residues:
Thr-308 and Ser-473. Phosphorylation of Thr-308, catalyzed by
PDK-1, is required for the AKT activity, and this activity is
augmented, ∼10-fold, by Ser-473 phosphorylation (Alessi et al.,
1996; Brazil et al., 2004). Besides functioning as a kinase toward
many substrates involved in these processes, AKT forms com-
plexes with other proteins that are not substrates, but rather act as
the modulators of the activity and function (Brazil et al., 2004).
AKT is highly expressed in different cell types (Brazil et al.,
2004). AKT has three isoforms in mammalian cells: AKT1,
AKT2, and AKT3, which have distinct roles in a variety of
processes, including development and metabolism (Dummler
and Hemmings, 2007). AKT1 is the most highly expressed iso-
form and is the isoform reported so far to be associated with
schizophrenia (Emamian et al., 2004). AKT2 is mainly involved
in regulation of metabolism primarily through insulin-regulated
glucose homeostasis. AKT2 is expressed at a lower level than
AKT1 and significant expression of AKT2 occurs in insulin-
responsive tissues, such as skeletal muscle, liver, heart, kid-
ney, and adipose tissue (Altomare et al., 1995; Chong et al.,
2005). During development of central nervous system (CNS),
the expression of AKT1 and AKT2 is increased during develop-
ment, but is gradually decreased during postnatal development
(Owada et al., 1997). In the adult brain, expression of AKT1
and AKT2 is initially weak. Unlike AKT1 and AKT2, AKT3 is
only expressed in specific tissues, such as in the brain and testes,
with lower expression evident in skeletal muscle, pancreas, heart,
and kidney (Chong et al., 2005). Although AKT3 is expressed
in the brain and has a role in postnatal brain development
(Birnbaum, 2004; Tschopp et al., 2005; Gonzalez and McGraw,
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FIGURE 1 | The AKT signaling pathway. AKT is activated by PI3K, which
itself is activated by several upstream signaling pathways such as insulin
receptors, receptor tyrosine kinases, G protein coupled receptors, cytokine
receptors, etc. After activation, it targets several downstream molecules and
change their activity by phosphorylation or complex formation. AKT is
involved in cell proliferation, glucose metabolism, cell survival, cell cycle,
protein synthesis, and in neuronal morphology and plasticity by regulation of
several downstream molecules shown in this figure. AKT is involved in cell
proliferation through interaction with a number of proteins involved in cell
cycle, including Cyclin D1, p21Cip, p27Kip, Myt1, and Wee1. AKT also
plays a crucial role in cell survival through interaction with Bad, MDM2
and the subsequent regulation of p53, FoxO1, Bcl-2, and Bax. AKT
regulates glucose metabolism through regulation of GSK-3, PFKFB2,
PIP5K, and AS160. It could also affect protein synthesis through
interaction with S6 kinase, TSC1, and mTOR signaling. In more recent
years, AKT’s role in neurodegeneration was uncovered, mediated
through phosphorylation of Huntingtin and Ataxin-1. AKT also has
a role in synaptic plasticity, by phosphorylation of GABAA receptor.
Pathway diagram reproduced courtesy of Cell Signaling Technology, Inc.
(www.cellsignal.com).
2009), there is not that much know about its association with
brain disorders. The focus of most studies related to schizophre-
nia is on AKT1, however, we cannot rule out the possible role
of other isoforms of AKT in schizophrenia (Birnbaum, 2004;
Freyberg et al., 2010).
AKT also plays a crucial role in cell survival (Brazil et al., 2004).
Enhanced AKT activity can foster cell survival against several
toxic insults such as matrix detachment (Rytomaa et al., 2000),
DNA damageHenry et al., 2001; Kang et al., 2003a,b; Chong et al.,
2005, anti-Fas antibody administration (Suhara et al., 2001),
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oxidative stress (Kang et al., 2003a,b; Chong et al., 2005), and
transforming growth factor-ß application (Conery et al., 2004).
Furthermore, many agents or growth factors can prevent apop-
totic cellular injury through the activation of AKT. In the vascular
system, angiopoietin-1 is an endothelium-specific ligand essential
for embryonic vascular stabilization, branching, morphogene-
sis, and post-natal angiogenesis. Angiopoietin-1 also supports
endothelial cell survival and prevents apoptosis through the acti-
vation of AKT (Papapetropoulos et al., 2000; Chong et al., 2005).
In the cardiovascular system, myocardial protection by insulin
during myocardial ischemia/reperfusion is eliminated by inhi-
bition of PI3-K, suggesting that cardioprotection of insulin is
mediated by AKT activation (Jonassen et al., 2001; Chong et al.,
2005). Other trophic factors and cytokines, such as erythropoi-
etin, may depend upon AKT to offer cellular protection (Chong
et al., 2005).
AKT IN NEURONS
Signaling through protein phosphorylation is of importance for
the normal development and function of the CNS. Protein phos-
phorylation is one of the most important mechanisms used in
the nervous system for the regulation of the specificity and effi-
cacy of neurotransmitter release from the presynaptic terminal in
response to the nerve impulse (Greengard et al., 1993; Greengard,
2001).
AKT has a basic role in regulating neuronal cell size and
survival (Franke, 2008; Niizuma et al., 2009; Freyberg et al.,
2010). AKT is a critical survival factor that can modulate cellu-
lar pathways involved in apoptosis. Over-expression of AKT in
cerebellar granule neurons prevents apoptosis during growth fac-
tor withdrawal (Dudek et al., 1997; Chong et al., 2005). However,
expression of a dominant-negative AKT or inhibition of PI3-K
attenuates neuronal cell survival normally supported by growth
factors (Maiese and Chong, 2004; Chong et al., 2005). Several
studies illustrated an important role for AKT for the survival
of various neuronal cell types during cell injury. AKT promotes
cell survival during free radical exposure in primary hippocam-
pal neurons (Matsuzaki et al., 1999; Chong et al., 2005), neuronal
cell lines (Kang et al., 2003a,b), and cerebral vascular endothelial
cells (Chong et al., 2005).
During the past decade, there has been emerging evidence
indicating several novel functions of AKT signaling pathway
in the brain. In the CNS, AKT prevents injury-induced neu-
ronal death and accelerates axonal regeneration (Namikawa et al.,
2000). Moreover, it is shown that AKT is required for NGF-
induced axon elongation and enhances axon branching (Markus
et al., 2002). Intriguingly, AKT also plays a role in neuronalmigra-
tion. Reelin, a large extracellular matrix protein responsible for
positioning of cortical neurons, contributes to final neuron posi-
tioning in the mammalian brain by local modulation of AKT
kinase activity (Beffert et al., 2002). The interesting study by Lin
et al. (2001) provides a key piece in discovery of the roles played
by AKT in the adult CNS. Their study shows AKT plays a cru-
cial role in synaptic plasticity and memory formation. Another
study by Mizuno et al. (2003) also shows that phosphorylation
of BDNF receptor tyrosine kinase B (TrkB), PI3-K and its tar-
get AKT in the hippocampus increased in parallel with spatial
memory formation (Mizuno et al., 2003). The study by Wang
et al. (2003) uncovered a novel function of AKT in CNS. They
discovered that AKT phosphorylates, both in vitro and in vivo,
the type A GABA receptor, the principal receptor mediating
fast inhibitory synaptic transmission, leading to increase in the
number of GABA receptors on the plasma membrane surface,
thereby increasing inhibitory fast synaptic transmission in neu-
rons. Another suggested mechanism for AKT’s role in synaptic
plasticity and memory is through regulation of the mammalian
target of rapamycin (mTOR). AKT is known to activate mTOR via
phosphorylation and inhibition of the TSC2 subunit of the tuber-
ous sclerosis complex (TSC). Interestingly, TSC2 heterozygous
mice, in which the mTORC1 signaling pathways is constitutively
active, exhibit impaired hippocampus-dependent memory that
is reversible by rapamcyin treatment (Klann and Dever, 2004;
Costa-Mattioli et al., 2009). Finally, the elegant study of Beaulieu
et al. (2005) showed that AKT in complex with beta-arrestin
2 and PP2A mediates the dopaminergic neurotransmission and
behavior.
Some other studies provided more interesting evidence show-
ing the direct role of AKT is synaptic function and plasticity.
AKT modulates synaptic plasticity and affects brain functions
such as long-term potentiation, working memory, and fear con-
ditioning (Lin et al., 2001; Lai et al., 2006; Sui et al., 2008;
Niizuma et al., 2009; Freyberg et al., 2010). AKT also plays a
role presynaptically through intracellular trafficking of biogenic
amine transporters including the dopamine and norepinephrine
transporters (Freyberg et al., 2010). Dopamine-mediated changes
in AKT activity are thought to be mediated by postsynaptic
dopamine D2 receptors (Beaulieu et al., 2007). In Drosophila,
a study by Guo and Zhong (2006) shows the requirement of
AKT for mediation of long-term depression. Moreover, in the
mouse hippocampus, it is been shown that activation of the PI3-
kinase and AKT is required for metabotropic glutamate receptor-
dependent long-term depression (Hou and Klann, 2004). More
evidence in support of this finding is provided by Lee et al. (2005),
which shows stimulation of postsynaptic density-95 (PSD-95)
protein translation by insulin via the PI3-kinase and AKT signal-
ing pathway. Prior to this study, another report by Akama and
McEwen (2003) shows that estrogen can also stimulate PSD-95
rapid protein synthesis via AKT signaling pathway.
AKT SIGNALING IN SCHIZOPHRENIA
Since the initial report in 2004 (Emamian et al., 2004), many other
studies have been published supporting that impaired AKT sig-
naling plays an important role in the pathogenesis of schizophre-
nia. This study and several subsequent ones uncovered association
between AKT1 genetic variants and schizophrenia in case/control
samples and family cohorts (Emamian et al., 2004; Ikeda et al.,
2004; Schwab et al., 2005; Bajestan et al., 2006). The origi-
nal study reported a significant association between schizophre-
nia and an AKT1 haplotype in U.S. families (Caucasian of
Northern European origin). The genetic association of AKT1with
schizophrenia was later confirmed in European (Schwab et al.,
2005), Japanese (Ikeda et al., 2004), Middle Eastern (Bajestan
et al., 2006), Chinese (Xu et al., 2007) and Irish (Thiselton
et al., 2008) populations. Taken together, despite the presence
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a negative report in a case-control Japanese population (Ohtsuki
et al., 2004), it seems that the genetic association of AKT with
schizophrenia is not limited to a specific genetic background and
is reproducible in populations with different backgrounds.
Some studies have tried to study the correlations of the original
SNPs reported in Emamian et al. (2004) with specific domains of
human brain function. For example, Tan et al. (2008) examined
the relationship of five originalAKT1 SNPs to cognition in healthy
subjects. They found that variants of the gene are associated with
differences in specific domains of cognitive function including IQ,
executive functioning, and processing speed. The executive func-
tioning domain of brain is one of cognitive domains affected in
schizophrenia (Sadock et al., 2009). Interestingly, Tan et al. also
found that the single SNPs that is associated with reduced expres-
sion of AKT1 in peripheral lymphocytes, is also associated with
brain volume reductions in caudate and right prefrontal cortex
(Tan et al., 2008).
AKT1 protein level is significantly reduced in different tissues
from patients with schizophrenia. Lymphocytes from individuals
with schizophrenia expressed 68% less AKT1 relative to control
subjects (Emamian et al., 2004). More importantly, AKT1 was
reduced in the hippocampus and frontal cortex in postmortem
brain samples from those with schizophrenia relative to com-
parison subjects. This decrease in protein level in the brain was
specific to AKT1 isoform and AKT2 and AKT3 levels were unaf-
fected (Emamian et al., 2004). Although some microarray studies
failed to find changes in AKT1 mRNA levels in the brain tis-
sue of schizophrenics (Horváth et al., 2011), a number of studies
provided convergent evidence of a decrease in AKT1 mRNA, pro-
tein, and activity levels in the prefrontal cortex and hippocampus,
as well as in peripheral blood of individuals with schizophrenia
(Emamian et al., 2004; Zhao et al., 2006; Thiselton et al., 2008).
The activity of major AKT1 targets such as GSK3 was also found
to be altered in individuals with schizophrenia (Emamian et al.,
2004). Several studies, described below, have since been pub-
lished that uncover specific molecular mechanisms underlying
the involvement of AKT signaling pathway in schizophrenia.
GSK-3 SIGNALING IN SCHIZOPHRENIA
Some studies have reported changes in the protein or activity
levels of GSK-3β in different tissues obtained from schizophre-
nia samples (Koros and Dorner-Ciossek, 2007). Yang et al first
reported decreased levels of GSK-3α proteins in lymphocytes
of individuals with schizophrenia (Yang et al., 1995). We saw a
statistically insignificant decrease in GSK-3β total protein levels
in lymphocyte of patients with schizophrenia (Emamian et al.,
2004). Further analysis of postmortem brains from patients with
schizophrenia confirmed decreased phosphorylation levels and
GSK-3β protein levels in the frontal cortex, as well as GSK-
3β mRNA levels in the dorsolateral prefrontal cortex (Emamian
et al., 2004; Kozlovsky et al., 2004; Koros and Dorner-Ciossek,
2007).
Psychopharmacological studies provide the most promising
evidence in support of the involvement of GSK-3β signaling in
schizophrenia. Several studies have reported that chronic admin-
istration of antipsychotics phosphorylates GSK-3β at the Ser-9
residue, and inhibits its activity (Emamian et al., 2004; Koros and
Dorner-Ciossek, 2007). More specifically, we saw chronic treat-
ment of mice with haloperidol can increase phosphorylation of
GSK-3β at Ser-9, which is associated with increased phosphoryla-
tion levels of AKT on both Thr-308 and Ser-473 phosphorylation
sites in the frontal cortex (Emamian et al., 2004). Other studies
also reported that chronic administration of clozapine, risperi-
done or haloperidol can enhance protein levels of β-catenin and
GSK-3 as well as the inhibitory phosphorylation of GSK-3β in
the rat prefrontal cortex and striatum (Alimohamad et al., 2005;
Kozlovsky et al., 2006). Atypical antipsychotics after acute admin-
istration can increase phosphorylation of GSK-3β in the mouse
brain (Li et al., 2007). Besides antipsychotics, lithium, and elec-
troconvulsive shocks used to augment antipsychotic treatment in
schizophrenic patients have been shown to lead to activation of
AKT and concomitant inhibition of GSK-3β in rats (Kang et al.,
2004; Gould, 2006).
Modulation of the activity of receptors of several neurotrans-
mitters involved in schizophrenia can affect GSK-3β activity
(Koros and Dorner-Ciossek, 2007). Administration of NMDA
ligand can dephosphorylate GSK-3β at Ser-9 which leads to its
activation (Luo et al., 2003). Consistent with this finding, non-
competitive antagonists of NMDA receptors can inhibit GSK-
3β by phosphorylation of Ser-9 site (Gould and Manji, 2005).
Dopamine receptor antagonists as well as chemicals enhancing
serotonergic transmission have been found to increase the expres-
sion and inhibitory phosphorylation of GSK-3β and activation of
AKT in the mouse brain (Li et al., 2004, 2007).
A BRIEF REVIEW OF OTHER SIGNALING PATHWAYS
INVOLVED IN SCHIZOPHRENIA
Besides the AKT/GSK3 signaling pathway described above, sev-
eral other signaling molecules have been identified during the
last decade to play an important role in schizophrenia. Signaling
molecules generally act through a network of proteins to con-
vey a signal from cell membrane to downstream molecules,
such as transcription factors in the nucleus. Therefore, signaling
molecules are functionally connected to each other and disrup-
tion in the function of one molecule could interfere with the
efficacy and efficiency of signal transduction from cell membrane
to the nucleus, which ultimately can result in the failure of cel-
lular function. In this section DISC1, NRG1, and calcineurin are
described as examples of intracellular molecules that are directly
associated with schizophrenia through both genetic and func-
tional studies. However, several other known signaling molecules
are reported to be involved in schizophrenia but they are not
discussed in this review due to the limitation of space.
DISRUPTED IN SCHIZOPHRENIA-1 (DISC1)
DISC1 is now widely accepted as one of the most important
candidate genes for schizophrenia. A wide range of genetic, pro-
teomic, and biochemical studies, have provided strong evidence
in support of the involvement of this gene in the development of
schizophrenia. This gene was initially reported in a pedigree of a
large Scottish family with many individuals displaying a variety
of psychiatric diagnoses including schizophrenia, bipolar disor-
der, recurrent depression, and conduct disorder (St Clair et al.,
1990). Genomic analysis of the pedigree revealed the presence
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of a t(1;11)(q42;q14) balanced chromosomal translocation which
cosegregated with mental illness in affected individuals, and
lead to a disruption of two genes, Disrupted In Schizophrenia-
1 (DISC1) and Disrupted In Schizophrenia-2 (DISC2) (Millar
et al., 2000; Kvajo et al., 2010). Linkage and association studies
linked DISC1 variants to schizophrenia, schizoaffective disorder,
and major depression (Allen et al., 2008). There are four splice
variants of the DISC1 gene including the L (Long; 90 kDa), Lv
(Long Variant; 95 kDa), S (Short; 70 kDa), and Es (Extremely
Short; 41 kDa) (Taylor et al., 2003). The Scottish translocation
occurs between exons 8 and 9 of the gene, truncating the C-
terminal region of the major (L, Lv, and S) isoforms (Millar
et al., 2000). The extremely short DISC1 isoform is present in
the Scottish translocation carriers (Taylor et al., 2003; Kvajo et al.,
2010).
At the protein level, DISC1 has an N-terminal domain with
no clear structure, and a long helical C-terminal domain con-
taining multiple regions with high coiled-coil forming potential,
which can bind multiple proteins involved in different cellular
processes (Millar et al., 2000). Recent studies provide evidence
for the connection between DISC1 and AKT signaling pathways.
For example, it has been recently shown that DISC1 regulates new
neuron development in the adult brain via modulation of AKT-
mTOR signaling through KIAA1212 (Kim et al., 2009). More
importantly, it has been shown that DISC1 binds phosphodi-
esterase 4b (PDE4b), an enzyme which inactivates cAMP, and is
believed to be the only way of cAMP degradation in the brain
(Millar et al., 2005).
In terms of subcellular localization, DISC1 has been reported
to localize in different compartments including the centrosome
(Morris et al., 2003), mitochondria (James et al., 2004), spines
and dendrites (Millar et al., 2005; Bradshaw et al., 2008), growth
cones and axon terminals in neurons and neuronal like cells (Taya
et al., 2007), stress granules (Ogawa et al., 2005) and the nucleus
(Sawamura et al., 2005). This pattern of localizations lead to a
suggestion that DISC1 may act as a molecular scaffold and serve
as an assembly point for large protein complexes (Kvajo et al.,
2010). During the development of the brain, DISC1 mRNA can
be detected in all hippocampal subfields, the cortex, and the thala-
mus. In the adult brain, however, DISC1 displays amore restricted
localization with a high expression only in the dentate gyrus of
the hippocampus, and, to a lesser degree in the CA1 region of
hippocampus (Austin et al., 2004).
A number of studies in human showed that healthy sub-
jects and patients with schizophrenia carrying DISC1 risk alleles
display changes in gray matter volume in the hippocampus, pre-
frontal cortex, and other brain regions (Callicott et al., 2005;
Cannon et al., 2005; Di Giorgio et al., 2008; Szeszko et al., 2008).
DISC1 risk alleles are also associated with deficits in working
memory, short-term memory, and long-term memory (Burdick
et al., 2005; Cannon et al., 2005; Hennah et al., 2005), atten-
tion (Hennah et al., 2005; Liu et al., 2006), and hippocampal and
prefrontal cortical activation (Callicott et al., 2005; Prata et al.,
2008).
Deficiency in DISC1 expression in mice caused region-specific
phenotypes, including altered organization and complexity of
newly born and mature neurons of the dentate gyrus, as well
as changes in short-term plasticity in CA3/CA1 synapses (Kvajo
et al., 2008). DISC1 deficient mouse shows highly selective
impairment in working memory as well (Koike et al., 2006; Kvajo
et al., 2008). Other mouse models of DISC1 have been generated
that show selective cognitive behavioral phenotypes (Clapcote
et al., 2007; Hikida et al., 2007; Pletnikov et al., 2007, 2008).
Overexpression of truncated versions of the human DISC1 also
provided evidence for anatomical and behavioral abnormalities
(Hikida et al., 2007; Pletnikov et al., 2007, 2008). Moreover,
mice carrying point mutations in the DISC1 gene demonstrated
that allelic heterogeneity at the DISC1 locus can lead to distinct
behavioral phenotypes (Clapcote et al., 2007; Kvajo et al., 2010).
NEUREGULIN 1 (NRG1)
Several review articles have been already published that dis-
cuss the genetic, neurobiological, and pathophysiologic studies
of NRG1 and ErbB4 in schizophrenia (Mei and Xiong, 2008;
Talmage, 2008; Jaaro-Peled et al., 2009; Banerjee et al., 2010).
NRG1 is also one of the most important schizophrenia suscep-
tibility genes, for which risk genotypes or haplotypes have been
identified and its associations with the illness have been replicated
in different populations (Mei and Xiong, 2008; Banerjee et al.,
2010).
NRG1 has diverse neurobiological functions, some of which
have been implicated in the pathophysiology of schizophrenia
(Mei and Xiong, 2008; Talmage, 2008; Jaaro-Peled et al., 2009;
Banerjee et al., 2010). These functions include neuronal migra-
tion, neuro-glial trophic effects, myelination and modulation of
glutamatergic or GABAergic neurotransmitter systems (Mei and
Xiong, 2008; Talmage, 2008; Jaaro-Peled et al., 2009; Banerjee
et al., 2010). Moreover, there is genetic evidence for ErbB4, tyro-
sine kinase receptor, as a candidate susceptibility gene as well
as a positive epistatic interactions between NRG1 and ErbB4 in
schizophrenia. ErbB4 interacts with NRG1 and influences gluta-
matergic and GABAergic and neurotrophic transmissions. These
neurotransmitter systems have all been implicated in the patho-
genesis of schizophrenia. Therefore, there is a significant body
of literature supporting the role of NRG1–ErbB4 signaling path-
way in the development of schizophrenia (Mei and Xiong, 2008;
Talmage, 2008; Jaaro-Peled et al., 2009; Banerjee et al., 2010).
While genetic, neurobiological and endophenotypic investiga-
tions support the role of the NRG1–ErbB4 pathway in schizophre-
nia, there are recent evidence showing that this pathway could
act along with other signaling molecules involved in schizophre-
nia (Banerjee et al., 2010). Positive association of NRG1 with
schizophrenia has been replicated in various populations. Some
genotype–phenotype association studies have demonstrated links
between risk genotypes of NRG1 and some of the disease mani-
festations of schizophrenia (Banerjee et al., 2010). However, most
disease endophenotypes were not associated with the NRG1 or
ErbB4 risk haplotypes, but rather with a single nucleotide poly-
morphism within the hapblocks (Mei and Xiong, 2008; Talmage,
2008; Jaaro-Peled et al., 2009; Banerjee et al., 2010). Interestingly,
recent studies by Nicodemus et al. (2010) show evidence of
increased schizophrenia risk with NRG1, ErbB4, and AKT1 epis-
tasis via functional neuroimaging in healthy controls (Nicodemus
et al., 2010). The same group also reported epistatic and
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functional interactions of catechol-O-methyltransferase (COMT)
and AKT1 on NRG1-ErbB signaling (Sei et al., 2010).
CALCINEURIN (PROTEIN PHOSPHATASE 2B OR PP2B)
Calcineurin is a calcium/calmodulin dependent Ser/Thr phos-
phatase and is widely expressed in the brain and other tissues. It
dephosphorylates a large number of signaling proteins and, there-
fore, is involved in the regulation of several neuronal processes
(Shibasaki et al., 2002). Calcineurin was first linked to schizophre-
nia by the study of Gerber et al. (2003). Gerber et al. studied
a subset of calcineurin-related genes that map to loci previ-
ously implicated in schizophrenia by linkage studies and detected
association of the PPP3CC gene, which encodes the calcineurin
gamma catalytic subunit, with schizophrenia. Some studies could
reproduce this finding (Goto et al., 1986; Horiuchi et al., 2007;
Liu et al., 2007; Yamada et al., 2007) and some failed to show an
association, possibly due to the power of the studies and the level
of risk associated with altered calcineurin signaling (Kinoshita
et al., 2005; Xi et al., 2007; Sanders et al., 2008; Kvajo et al.,
2010). Regardless of genetic association, calcineurin is function-
ally important because it can affect the activity of several other
signaling molecules involved in schizophrenia (described below).
MOLECULAR MECHANISMS UNDERLYING THE ROLE
OF AKT/GSK3 PATHWAY IN SCHIZOPHRENIA
AKT is recruited to the cell membrane by binding to lipids
generated by PI3 kinase (Brazil et al., 2004). In response to lig-
and binding to plasma membrane receptors of different tyrosine
kinases, PI3K generates phosphatidylinositol 3,4,5 trisphosphate
(PIP3) at the cell surface, which leads to recruitment of AKT to the
plasma membrane through its association with the newly gener-
ated PIP3 (Brazil et al., 2004). AKT is subsequently activated by
phosphorylation at Thr-308, catalyzed by PDK1. A second phos-
phorylation at Ser-473, by an unknown kinase, can augment its
activity up to 10-folds (Brazil et al., 2004). Activated AKT phos-
phorylates a number of other molecules including the clinically
relevant target, GSK3 (Figure 1, Brazil et al., 2004). GSK3 plays
several roles in glucose metabolism, differentiation and develop-
ment, intracellular trafficking, apoptosis, and regulation of gene
transcription (Kockeritz et al., 2006). In the brain, some studies
suggest that GSK3, like AKT, could modulate synaptic plasticity
(Peineau et al., 2008). Unlike AKT that has to be phosphorylated
before activation (Brazil et al., 2004), GSK3 is constitutively active
in resting cells, requiring phosphorylation by kinases such as AKT
to inactivate it (Doble and Woodgett, 2003).
Signaling through Wnt pathway has been also reported to be
involved in schizophrenia. The Wnt signaling plays a critical role
in a variety of developmental processes during embryonic devel-
opment but recent studies have also suggested a role for the Wnt
pathway in synaptic modulation and plasticity during the adult
life (Hall et al., 2000). GSK-3β is an intermediate cytoplasmic
component in Wnt pathway (Nelson and Nusse, 2004). GSK-3β
forms a complex with multiple proteins such as β-catenin, APC
and Axin (Lovestone et al., 2007). GSK-3β constitutively phos-
phorylates β-catenin, which results in its degradation and the
subsequent inhibition of β-catenin-mediated gene transcription.
Activation of Wnt receptor facilitates the physical separation of
GSK-3β from β-catenin (Lovestone et al., 2007). This separation
blocks phosphorylation of β-catenin by GSK-3β, which prevents
degradation of β-catenin and causes its nuclear localization. In
the nucleus, β-catenin regulates transcription and expression of
specific proteins in the cell (Lovestone et al., 2007). Postmortem
studies showed decreased in β-catenin levels (Lovestone et al.,
2007) and an increased expression of Wnt-1 in the brain samples
from patients with schizophrenia (Miyaoka et al., 1999). Taken
together, many reports consistently showed the involvement of
AKT-GSK3-Wnt pathway in schizophrenia, which makes them an
attractive target for development of novel therapeutics for treat-
ment of schizophrenia and other psychiatric disorders (Freyberg
et al., 2010).
An interesting study by Mao et al. (2009) reported an interac-
tion between DISC1 and GSK-3β that plays a role in neurogenesis
during brain development and adulthood (Mao et al., 2009).
Reduction of the expression of DISC1 in neurons decreases neu-
rogenesis mediated by β-catenin signaling (Mao et al., 2009).
More specifically, DISC1 can directly bind to GSK-3β and inhibit
its activity. This inhibition interferes with its ability to phospho-
rylate β-catenin. It also affects GSK-3β’s auto-phosphorylation
at Y216. Interestingly, DISC1-mediated inhibition of GSK-3β
affects a selective set of GSK-3β substrates and some of the well-
characterized targets apparently are not affected. As discussed
above, GSK-3β is immediate downstream molecule to the AKT
and a key player of Wnt signaling pathways (Freyberg et al.,
2010). This new interaction adds another interesting dimension
in support of the convergent evidence for the involvement of
AKT/GSK3 signaling pathway in schizophrenia that needs to be
dissected out with further studies.
Dopamine receptors have been the center of attention of sev-
eral groups to investigate how AKT is involved in schizophrenia.
Dopamine D2 class receptors (D2−4 receptors) can modulate the
activity of AKT (Beaulieu et al., 2007). Activation of dopamine
D2 receptor by dopamine leads to recruitment of β-arrestin 2,
a scaffolding protein, which facilitates receptor desensitization
and the subsequent internalization (Beaulieu et al., 2005). AKT
is also recruited into this complex along with the phosphatase
PP2A. PP2A dephosphorylates and inactivates AKT, leading to
an increased GSK3 activity (Beaulieu et al., 2004, 2005; Klewe
et al., 2008; Skinbjerg et al., 2009). Beaulieu et al. also showed
that activation of dopamine D2 receptor can inhibit AKT activ-
ity through an arrestin-dependent but G protein-independent
pathway (Beaulieu et al., 2005, 2007). This interesting observa-
tion shed new light on the mechanisms of antipsychotic action
of the D2 receptor blockers. In other words, antipsychotic med-
ications may prevent β-arrestin 2 recruitment through blocking
dopamine D2 receptor (Klewe et al., 2008; Masri et al., 2008)
and the subsequent activation of AKT. The same group has
shown similar function for lithium, which is essentially a mood
stabilizer not an antipsychotic drug. Lithium has been shown
to disrupt the β-arrestin 2/AKT/PP2A complex, thereby pre-
venting dopamine-induced dephosphorylation of AKT, which
is associated with reversal of amphetamine-induced locomotion
(Beaulieu et al., 2005).Moreover, amphetamine-induced locomo-
tion is greatly diminished in β-arrestin 2 knockout mice, suggest-
ing that this pathway is critical to at least some psychostimulant
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effects (Beaulieu et al., 2005). Several studies have shown that
schizophrenia and bipolar mood disorder (BMD) share several
genes and pathways that are critically involved in both disor-
ders. However, the clinical phenotypes of these two disorders are
very different. It is not clear how two entirely different classes
of psychotropic drugs, i.e., antipsychotics and mood stabilizers,
act through similar signaling pathways but produce completely
different clinical pictures.
TRANSCRIPTION FACTORS RELATED TO SCHIZOPHRENIA
AKT and GSK3 can modulate the activity of several transcrip-
tion factors; therefore, they can change the expression patterns of
many genes that are regulated by those transcription factors. Some
transcription factors are reported to be directly associated with
schizophrenia.AssociationbetweenTranscriptionFactor4 (TCF4)
and schizophrenia has been recently reported, which influences
verbal learning andmemory functioning in schizophrenia patients
(Lennertz et al., 2011; Williams et al., 2011). Variants of the v-rel
avian reticuloendotheliosis viral oncogene homolog A (RELA)
gene are associated with schizophrenia and their startle responses
(Hashimoto et al., 2011). RELA encodes the major component of
the nuclear factor kappa B (NF-κB) complex that has important
roles in the immune and inflammatory responses. The association
between RELA gene and schizophrenia was evident in male sub-
jects but not in female subjects (Song et al., 2009;Hashimoto et al.,
2011). Postmortem studies showed decreased in β-catenin levels
(Lovestoneetal., 2007)andan increasedexpressionofWnt-1 in the
brain samples from subjects with schizophrenia (Miyaoka et al.,
1999). Georgieva et al. (2006) provided convergent evidence for
the involvement of transcription factor oligodendrocyte lineage 2
(OLIG2) in schizophrenia. They show variation in OLIG2 confers
susceptibility to schizophrenia alone and as part of a network of
genes implicated in oligodendrocyte function (Georgieva et al.,
2006).
Some important signaling molecules that show association
with schizophrenia could affect transcriptional activity of other
transcription factors as well. For example, calcineurin (PP2B)
can directly regulate the activity of CREB and Nuclear Factor of
Activated T cells (NFATc), which are both involved in cognitive
functions known to be impaired in schizophrenia. CREB not only
is known to be involved in depression (Carlezon et al., 2005), but
also some variants in the promoter region of CREB in patients
with schizophrenia have been reported as well (Kawanishi et al.,
1999). Kawanishi and colleagues analyzed the promoter region
of the human CREB in schizophrenics and healthy subjects and
found two novel variants (−933T–>C and −413G–>A) only in
schizophrenics. Calcineurin can activate the transcription factor
NFAT, which has a role in neuronal growth and axonal guidance
during development in vitro. Interestingly, NFAT mutant mice
shows severe neurodevelopmental defects in vivo (Graef et al.,
2001).
CONCLUSION
Review of the literature published during the past few years pro-
vide strong support for the involvement of AKT/GSK3 signaling
pathway in the development of schizophrenia. A number of
studies strongly suggest targeting this pathway is a promising
approach for development of novel psychotropic drugs for treat-
ment of schizophrenia and mood disorders. At the same time,
there are several other signaling molecules and pathways that
show conclusive evidence for being involved in pathogenesis of
schizophrenia. Despite many differences in the approach of sci-
entists working on schizophrenia, they have come to a general
consensus that schizophrenia is most likely caused by the altered
function or expression of many genes. Such genes may individu-
ally contribute only to a small risk, but their cumulative effects
cause the dysfunction of brain, which manifests itself by the
clinical picture we call schizophrenia. Although there has been
significant progress in identification of the role of several sig-
naling molecules in schizophrenia, we still do not know how
much each gene contributes to the development of pathology.
Therefore, we need to develop novel systems biology tools that
can quantify the role of individual or multiple genes in disease
development. The recently developed fault diagnosis engineering
technology in molecular networks is a promising tool that has
such capabilities and can model complex trait disorders such as
schizophrenia (Abdi et al., 2008, 2009; Emamian and Abdi, 2009;
Abdi and Emamian, 2010).
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